Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy

Takeshi Yamada, Akihisa Matsuda, Goro Takahashi, Takuma Iwai, Kohki Takeda, Kohji Ueda, Sho Kuriyama, Michihiro Koizumi, Seiichi Shinji, Yasuyuki Yokoyama, Ryo Ohta, Hiroshi Yoshida